◎ Sugi Atlas

Atlas / Drug / Cannabidiol

Cannabidiol

drug
On this page

Also known as (-)-cannabidiol(-)-cbd(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiolBTX-1204BTX-1503Cannabidiol solutionCardiolrxEpidiolexEpidyolexGWP-42003GWP42003Cannabidiol (CBD)CannabidiolÊCannabidiolÂ

Summary

Cannabidiol (CHEMBL190461) is an approved small-molecule antimicrobial agent (ATC N03AX24) targeting GPR55, TRPA1, and TRPM8; indicated across 90 conditions including epilepsy and visual epilepsy.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: N03AX24
  • Targets: 15 (GPR55, TRPA1, TRPM8…)
  • Indications: 90 conditions
  • Clinical trials: 236
  • Chemistry: 314.5 Da · C21H30O2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL190461
NameCannabidiol
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID644019
ChEBICHEBI:69478
ATCN03AX24
Molecular formulaC21H30O2
Molecular weight314.5
InChIKeyQHMBSVQNZZTUGM-ZWKOTPCHSA-N

SMILES: CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O

IUPAC name: 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol

ChEBI definition: An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.

Pharmacological roles (ChEBI): antimicrobial agent.

Other ChEBI roles (chemical / environmental): plant metabolite.

Also known as: (-)-cannabidiol, (-)-cbd, (-)-trans-cannabidiol, .delta.1(2)-trans-cannabidiol, BTX-1204, BTX-1503, Cannabidiol, Cannabidiol solution, Cardiolrx, Epidiolex, Epidyolex, GWP-42003

Patent coverage: 9,916 distinct patent families (26,379 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
GPR55GPR55Antagonist6.460%Q9Y2T6
TRPA1TRPA1Agonist6.320.1%O75762
TRPM8TRPM8Antagonist5.550.5%Q7Z2W7
TRPV2TRPV2Activation4.51.4%Q9Y5S1
TRPV3TRPV3Activation5.430%Q8NET8
CNR1CB1 receptorNegative0%P21554
SCN1ANav1.14.90%P35498
SCN2ANav1.25.540.1%Q99250
SCN3ANav1.35.480.1%Q9NY46
SCN4ANav1.450%P35499
SCN5ANav1.55.420.2%Q14524
SCN8ANav1.65.520.7%Q9UQD0
SCN9ANav1.76.70%Q15858
SCN10ANav1.85.70.1%Q9Y5Y9
GPR18GPR18Partial agonist4.290.2%Q14330

Broader ChEMBL bioactivity targets: 66 (assay-derived). Sample: Transient receptor potential cation channel subfamily M member 8, G-protein coupled receptor 55, 5-hydroxytryptamine receptor 2B, Cholecystokinin receptor type A, Alpha-2C adrenergic receptor, Gamma-aminobutyric acid receptor subunit beta-2, Alpha-2B adrenergic receptor, Equilibrative nucleoside transporter 1, D(1A) dopamine receptor, Thromboxane A2 receptor.

Bioactivity

ChEMBL activities: 98 potent at pChembl ≥ 5 of 120 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
DRD210.18Ki0.07nMCHEMBL_ACT_29084137
CNR28.1EC507.94nMCHEMBL_ACT_24665532
CNR28.1EC507.94nMCHEMBL_ACT_24665545
CNR27.9EC5012.59nMCHEMBL_ACT_24665542
CNR27.9EC5012.59nMCHEMBL_ACT_24665550
CNR27.9EC5012.59nMCHEMBL_ACT_24665566
CNR27.8EC5015.85nMCHEMBL_ACT_24665524
CASP17.73Kd18.8nMCHEMBL_ACT_23295279
CNR27.6EC5025.12nMCHEMBL_ACT_24665517
CNR27.5EC5031.62nMCHEMBL_ACT_24665578
CNR27.4EC5039.81nMCHEMBL_ACT_24665514
CNR27.4EC5039.81nMCHEMBL_ACT_24665538
CNR27.4EC5039.81nMCHEMBL_ACT_24665553
CNR27.4EC5039.81nMCHEMBL_ACT_24665560
CNR27.3EC5050.12nMCHEMBL_ACT_24665506
CNR27.3EC5050.12nMCHEMBL_ACT_24665511
TRPM87.22IC5060nMCHEMBL_ACT_25073079
Q8R4557.22IC5060nMCHEMBL_ACT_29084132
Q6RI867.02EC5096nMCHEMBL_ACT_3301091
P220027IC50100nMCHEMBL_ACT_15777529
CNR26.98EC50104nMCHEMBL_ACT_25917771
PDE9A6.96IC50110nMCHEMBL_ACT_26183821
Q6RI866.96EC50110nMCHEMBL_ACT_29084131
GABRB26.89IC50130nMCHEMBL_ACT_25933720
CYP1A16.82Ki150nMCHEMBL_ACT_18157610
CNR16.82Ki151nMCHEMBL_ACT_25917765
CYP1A16.8Ki160nMCHEMBL_ACT_22482096
CYP3A56.72Ki190nMCHEMBL_ACT_22482114
P479366.64Ki230nMCHEMBL_ACT_413978
CNR26.6EC50251.2nMCHEMBL_ACT_24665590

Target pathways

Aggregated over 15 target gene(s): GPR55, TRPA1, TRPM8, TRPV2, TRPV3, CNR1, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A, SCN10A, GPR18.

Top Reactome pathways

14 total, by targets touching each:

PathwayTargetsGenes
Developmental Biology8SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
L1CAM interactions8SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
Muscle contraction8SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
Axon guidance8SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
Interaction between L1 and Ankyrins8SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
Cardiac conduction8SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
Phase 0 - rapid depolarisation8SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
Nervous system development8SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
TRP channels4TRPA1, TRPM8, TRPV2, TRPV3
Class A/1 (Rhodopsin-like receptors)3CNR1, GPR18, GPR55
G alpha (i) signalling events3CNR1, GPR18, GPR55
Sensory Perception3SCN2A, SCN3A, SCN9A
Sensory perception of taste3SCN2A, SCN3A, SCN9A
Sensory perception of sweet, bitter, and umami (glutamate) taste3SCN2A, SCN3A, SCN9A

Dominant GO biological processes

GO termTargets
monoatomic ion transport12
monoatomic ion transmembrane transport12
transmembrane transport12
sodium ion transmembrane transport9
sodium ion transport8
cardiac muscle cell action potential involved in contraction8
monoatomic cation transmembrane transport7
action potential6
regulation of heart rate6
calcium ion transmembrane transport4
calcium ion transport4
membrane depolarization during action potential4
cardiac muscle cell action potential4
regulation of muscle system process4
G protein-coupled receptor signaling pathway3

Indications & clinical

Indications

90 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
epilepsy4MONDO:0005027EFO:0000474
visual epilepsy4MONDO:0001386HP:0001250
hamartoma4MONDO:0006499EFO:1000634
Lennox-Gastaut syndrome4MONDO:0016532MONDO:0016532
schizoaffective disorder3MONDO:0005487EFO:0005411
psychotic disorder3MONDO:0005485EFO:0005407
fibromyalgia3MONDO:0005546EFO:0005687
osteoarthritis, knee3MONDO:0005416EFO:0004616
insomnia3MONDO:0013600EFO:0004698
amyotrophic lateral sclerosis3MONDO:0004976MONDO:0004976
breast neoplasm3MONDO:0021100MONDO:0007254
fragile X syndrome3MONDO:0010383MONDO:0010383
Rett syndrome3MONDO:0010726MONDO:0010726
bipolar disorder3MONDO:0004985MONDO:0004985
motor neuron disorder3MONDO:0020128EFO:0003782
graft versus host disease2MONDO:0013730EFO:0004599
anxiety2MONDO:0011918EFO:0005230
neoplasm2MONDO:0005070EFO:0000616
post-traumatic stress disorder2MONDO:0005146EFO:0001358
fatty liver disease2MONDO:0004790HP:0001397
ulcerative colitis2MONDO:0005101EFO:0000729
cocaine dependence2MONDO:0005186EFO:0002610
opiate dependence2MONDO:0005530EFO:0005611
Crohn disease2MONDO:0005011EFO:0000384
nicotine dependence2MONDO:0008575EFO:0003768
HIV infectious disease2MONDO:0005109EFO:0000764
autoimmune hepatitis2MONDO:0016264EFO:0005676
cannabis dependence2MONDO:0005689EFO:0007191
diabetic neuropathy2MONDO:0006626EFO:1000783
psoriatic arthritis2MONDO:0011849EFO:0003778
peripheral neuropathy2MONDO:0005244EFO:0003100
autism spectrum disorder2MONDO:0005258EFO:0003756
autism2MONDO:0005260EFO:0003758
neuralgia2MONDO:0021667EFO:0005762
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
obsessive-compulsive disorder2MONDO:0008114EFO:0004242
intellectual disability2MONDO:0001071HP:0001249
Tourette syndrome2MONDO:0007661EFO:0004895
sleep disorder2MONDO:0100081EFO:0008568
trichotillomania2MONDO:0013189HP:0012167
Parkinson disease2MONDO:0005180MONDO:0005180
migraine disorder2MONDO:0005277MONDO:0005277
alcohol abuse2MONDO:0002046MONDO:0007079
Huntington disease2MONDO:0007739MONDO:0007739
Prader-Willi syndrome2MONDO:0008300MONDO:0008300
Sturge-Weber syndrome2MONDO:0008501MONDO:0008501
benign essential blepharospasm2MONDO:0011728Orphanet:93955
glioblastoma2MONDO:0018177EFO:0000519
injury2MONDO:0021178EFO:0000546
pericarditis2MONDO:0005904EFO:0007427
social phobia2MONDO:0001247EFO:1001917
mental disorder2MONDO:0005084EFO:0000677
rheumatoid arthritis2MONDO:0008383EFO:0000685
endometriosis2MONDO:0005133EFO:0001065
bone fracture2MONDO:0005315EFO:0003931
carpal tunnel syndrome2MONDO:0007275EFO:0004143
Alzheimer disease2MONDO:0004975MONDO:0004975
osteoarthritis2MONDO:0005178MONDO:0005178
multiple sclerosis2MONDO:0005301MONDO:0005301
mucopolysaccharidosis type 22MONDO:0010674MONDO:0010674
long COVID-192MONDO:0100233MONDO:0100233
essential tremor1MONDO:0003233EFO:0003108
heart failure1MONDO:0005252EFO:0003144
interstitial cystitis1MONDO:0018301EFO:0008507
lung neoplasm1MONDO:0021117MONDO:0008903
prostate adenocarcinoma1MONDO:0005082EFO:0000673
radiculopathy1MONDO:0002959MONDO:0002959
hypertensive disorder1MONDO:0005044EFO:0000537
drug dependence0MONDO:0005303EFO:0003890
anorexia nervosa0MONDO:0005351MONDO:0005351

20 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 236.

Phase distribution

PhaseTrials
PHASE289
PHASE330
PHASE128
Not specified28
PHASE1/PHASE221
EARLY_PHASE118
PHASE2/PHASE312
PHASE410

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05044819PHASE4ACTIVE_NOT_RECRUITINGAssessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
NCT05649059PHASE4RECRUITINGInvestigating the Effects of Cannabidiol on Social Anxiety Disorder
NCT06924827PHASE4NOT_YET_RECRUITINGA Study to Investigate the Transition of Children From ‘Artisanal Cannabidiol (CBD) to Epidiolex
NCT03891264PHASE4TERMINATEDInvestigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain
NCT04133480PHASE4WITHDRAWNInvestigation of Cognitive Outcomes With Cannabidiol Oral Solution
NCT04607603PHASE4COMPLETEDEfficacy of Cannabidiol in Knee Osteoarthritis
NCT04749628PHASE4COMPLETEDCannabidiol for Bilateral Total Knee Arthroplasty
NCT04899050PHASE4COMPLETEDEpidiolex in Typical Absence Seizures
NCT05324449PHASE4COMPLETEDEpidiolex® for Anxiety in Pediatric Epilepsy
NCT05864846PHASE4COMPLETEDA Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
NCT04411225PHASE3RECRUITINGEffects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
NCT05020028PHASE2/PHASE3RECRUITINGCannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis
NCT05613608PHASE2/PHASE3RECRUITINGAlcohol Use Disorder and Cannabidiol
NCT05867849PHASE3RECRUITINGCannabidiol for Bipolar Depression (CBD-BD)
NCT06333041PHASE2/PHASE3RECRUITINGStudy of Cannabidiol in Sanfilippo Syndrome
NCT06708299PHASE3RECRUITINGCardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
NCT06940674PHASE3RECRUITINGAdjunctive Cannabidiol for Recovery From Opioid Study
NCT07123467PHASE3RECRUITINGCannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder
NCT07148206PHASE3NOT_YET_RECRUITINGDronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
NCT07148843PHASE2/PHASE3NOT_YET_RECRUITINGCannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
NCT07434973PHASE3NOT_YET_RECRUITINGStratification and Treatment in Early Psychosis Study - PROMOTE
NCT02091375PHASE3COMPLETEDAntiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
NCT02224560PHASE3COMPLETEDEfficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
NCT02224573PHASE3COMPLETEDAn Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes
NCT02224690PHASE3COMPLETEDA Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
NCT02224703PHASE3COMPLETEDGWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
NCT02318537PHASE3WITHDRAWNCannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
NCT02318563PHASE3WITHDRAWNCannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome
NCT02318602PHASE3COMPLETEDCannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
NCT02544750PHASE3COMPLETEDAn Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
NCT02544763PHASE3COMPLETEDA Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
NCT02783092PHASE3UNKNOWNA Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy
NCT02953548PHASE3COMPLETEDTrial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
NCT02954887PHASE3COMPLETEDPhase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
NCT03310593PHASE2/PHASE3TERMINATEDCannabidiol as an Adjunctive Treatment for Bipolar Depression
NCT03421496PHASE3TERMINATEDA Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms
NCT03467620PHASE2/PHASE3WITHDRAWNCannabidiol Usage as an Adjunct Therapy for Crohn’s Disease
NCT03848832PHASE3TERMINATEDEfficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
NCT04252586PHASE3TERMINATEDA Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
NCT04271917PHASE3COMPLETEDAnalgesic Effects of Cannabidiol for Simple Tooth Extractions in Dental Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 8 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

349 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
IMIPRAMINEChEMBL + PubChemPhase 4 (approved)CNR1, SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
SERTINDOLEChEMBLPhase 4 (approved)CNR1, SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
NITRENDIPINEChEMBLPhase 3CNR1, SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
AMIODARONEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
AMITRIPTYLINEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
CHLORPROMAZINEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
DILTIAZEMChEMBL + PubChemPhase 4 (approved)SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
HALOPERIDOLChEMBL + PubChemPhase 4 (approved)SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
LamotrigineChEMBL + PubChemPhase 4 (approved)SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
MEXILETINEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
NIFEDIPINEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
PIMOZIDEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
MIBEFRADILChEMBLPhase 4 (approved)SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
AJMALINEChEMBLPhase 3SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
ELECLAZINEChEMBLPhase 3SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
TEDISAMILChEMBLPhase 3SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
VIXOTRIGINEChEMBLPhase 3SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
CIFENLINEChEMBLPhase 2SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
TETRACAINEChEMBL + PubChemPhase 4 (approved)CNR1, SCN1A, SCN2A, SCN3A, SCN5A, SCN8A, SCN9A
TETRODOTOXINChEMBLPhase 3SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
PF-05089771ChEMBLPhase 2SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A
CarbamazepineChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN9A
LidocaineChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN9A
CANNABIDIVARINChEMBLPhase 2CNR1, GPR55, TRPA1, TRPM8, TRPV2, TRPV3
TETRAHYDROCANNABIVARINChEMBLPhase 2CNR1, GPR55, TRPA1, TRPM8, TRPV2, TRPV3
DofetilidePubChemApprovedSCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A
CaffeineChEMBL + PubChemPhase 4 (approved)CNR1, SCN1A, SCN2A, SCN3A, TRPA1
DRONABINOLChEMBL + PubChemPhase 4 (approved)CNR1, GPR18, GPR55, TRPA1, TRPM8
FELODIPINEChEMBL + PubChemPhase 4 (approved)CNR1, SCN1A, SCN2A, SCN3A, SCN5A
NISOLDIPINEChEMBL + PubChemPhase 4 (approved)CNR1, SCN1A, SCN2A, SCN3A, SCN5A
PHENYTOINChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN4A, SCN5A
BEPRIDILChEMBLPhase 4 (approved)CNR1, SCN1A, SCN2A, SCN3A, SCN5A
PRENYLAMINEChEMBLPhase 4 (approved)CNR1, SCN1A, SCN2A, SCN3A, SCN5A
CANNABIGEROLChEMBLPhase 2CNR1, TRPA1, TRPM8, TRPV2, TRPV3
FUNAPIDEChEMBLPhase 2SCN10A, SCN2A, SCN5A, SCN8A, SCN9A
BUSPIRONEChEMBL + PubChemPhase 4 (approved)CNR1, SCN1A, SCN2A, SCN3A
DESIPRAMINEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN5A
DIBUCAINEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN5A
DIPHENHYDRAMINEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN5A
DROPERIDOLChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN5A
FLUPHENAZINEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN5A
LOPERAMIDEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN5A
QUINIDINEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN5A
RILUZOLEChEMBL + PubChemPhase 4 (approved)SCN2A, SCN4A, SCN5A, SCN9A
THIORIDAZINEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN5A
VERAPAMILChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN5A
ETIDOCAINEChEMBLPhase 4 (approved)SCN1A, SCN2A, SCN3A, SCN5A
MIANSERINChEMBLPhase 4 (approved)CNR1, SCN1A, SCN2A, SCN3A
CANNABINOLChEMBLPhase 3CNR1, TRPA1, TRPV2, TRPV3
DS-1971ChEMBLPhase 2SCN2A, SCN5A, SCN8A, SCN9A
FLUNARIZINEChEMBLPhase 2CNR1, SCN1A, SCN2A, SCN3A
MEPRYLCAINEChEMBLPhase 2SCN1A, SCN2A, SCN3A, SCN5A
PF-04531083ChEMBLPhase 2SCN10A, SCN1A, SCN5A, SCN9A
BROMPHENIRAMINEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A
CHLORPHENIRAMINEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A
COCAINEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A
CYPROHEPTADINEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A
DICYCLOMINEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A
LEVORPHANOLChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A
PHENOXYBENZAMINEChEMBL + PubChemPhase 4 (approved)SCN1A, SCN2A, SCN3A

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot